O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life for patients struggling with severe respiratory distress. O11 has developed a disruptive therapy that allows patients to "breathe out" carbon dioxide via the intestines, freeing them from hours of agonizing ventilation therapy: RESPILIQ™. With currently 6 employees and its own production and development facility in Aachen, O11 is ideally positioned for the future.
